Cell Surface Receptor-Targeted Therapy of Acute Myeloid Leukemia: A Review
- 1 October 2000
- journal article
- review article
- Published by Mary Ann Liebert Inc in Cancer Biotherapy & Radiopharmaceuticals
- Vol. 15 (5) , 459-476
- https://doi.org/10.1089/cbr.2000.15.459
Abstract
Combination chemotherapy produces remissions in patients with acute myeloid leukemia (AML). However, the majority of patients ultimately relapse and die with cytotoxic drug resistant blasts. Novel agents which circumvent resistance are needed. One such class are AML-cell surface targeted proteins. These genetically engineered polypeptides are hybrid molecules composed of two moieties--a haptophore which triggers AML cell binding and a toxophore which kills the cell. The haptophore or ligand portion consists of a monoclonal antibody or antibody fragment or a cytokine. These peptides react with cell surface receptors or antigens on AML cells. The haptophore is genetically or chemically linked to the toxophore. The toxophore may consist of an antibody Fc domain which triggers antibody-dependent cell cytotoxicity, a DNA-damaging cytotoxic drug, a radionuclide or a protein synthesis-inactivating peptide toxin. The toxophore may provide a cell death signal that overcomes standard resistance phenotypes. Further, the targeting provided by the haptophore may reduce normal tissue toxicities. This review describes some of the properties of the cell surface molecular targets, the reactive haptophores and toxophores and how these functional peptides have been optimally combined to kill leukemic blasts in patients with AML.Keywords
This publication has 41 references indexed in Scilit:
- Flow Cytometric Immunophenotypic Characterization of Pediatric and Adult Minimally Differentiated Acute Myeloid Leukemia (AML-M0)American Journal of Clinical Pathology, 2000
- TrueLeukemia, 1999
- Molecular modeling of the GM-CSF and IL-3 receptor complexesProtein Science, 1995
- Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient miceNature, 1994
- Calicheamicin γ 1 I and DNA: Molecular Recognition Process Responsible for Site-SpecificityScience, 1989
- Calicheamicin γ 1 I : an Antitumor Antibiotic That Cleaves Double-Stranded DNA Site SpecificallyScience, 1988
- Clonal Development, Stem-Cell Differentiation, and Clinical Remissions in Acute Nonlymphocytic LeukemiaNew England Journal of Medicine, 1987
- Treatment of acute myeloid leukemia cells in vitro with a monoclonal antibody recognizing a myeloid differentiation antigen allows normal progenitor cells to be expressed.Journal of Clinical Investigation, 1987
- Human GM-CSF: Molecular Cloning of the Complementary DNA and Purification of the Natural and Recombinant ProteinsScience, 1985
- One molecule of diphtheria toxin fragment a introduced into a cell can kill the cellCell, 1978